30.05.2013 - Danish Novo A/S has secured royalties on an upcoming competitor treatment to the age-related macular degeneration drug Lucentis.
In total, the Danish injected US$175m to push Phase III development of Ophtotec’s AMD drug Fovista (E10030). The company led a US$50m Series C financing and secured a share on future royalties with the anti-PDGF pegylated aptamer in exchange for US$125m.
In Phase IIb studies, dosing 449 patients with wet AMD with 6 monthly injections of Fovista plus Lucentis in the eye led to an 62% improvement of vision compared to Lucentis monotherapy after 6 months. Last year Roche’s VEGF-targeting angiogenesis blocker, which is distributed in Europe by Novartis, made more that 1.5bn in sales.
23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.
21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.